FDA Study Links Yaz, Yasmin and Other Similar Birth Control Pills to Increased Risk of Blood Clots


FDA Study Links Yaz, Yasmin and Other Similar Birth Control Pills to Increased Risk of Blood ClotsOverview: Women who use birth control pills such as Yaz and Yasmin may be exposed to a higher risk of blood clots, according to a new study published in the journal Contraception. According to the research, oral contraceptives containing drospirenone can increase the chances of developing arterial thrombotic events (ATE) and venous thromboembolic events (VTE) compared to other combined hormonal contraceptives. The study is the latest to confirm the link between blood clots and drospirenone-containing birth control pills such as Yaz and Yasmin, which have become the subject of thousands of personal injury lawsuits in the US.

  • A new study in the journal Contraception shows that women who use birth control pills containing the synthetic hormone drospirenone are twice as likely to experience ATE and 77 percent more likely to experience VTE
  • Drospirenone-based birth control pills such as Yaz and Yasmin have been linked to an increased risk of blood clots in previous research; the latest FDA label update warned that Yaz and Yasmin users may even have triple the risk
  • There are thousands of lawsuits in the US alleging that Yaz or Yasmin caused blood clots, gallbladder damage and other injuries

Product: Yaz, Yasmin (Drospirenone and Ethinyl Estradiol)

Manufacturer: Bayer AG                                  

Side Effects & Complications

  • Blood Clots
  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Gallbladder Damage
  • Heart Attacks
  • Stroke

The Study

The study, which was funded by the U.S. Food and Drug Administration (FDA), found that women who took birth control pills containing drospirenone were 77 percent more likely to develop VTE and twice as likely to suffer from ATE compared to those who took another type of combined hormonal contraceptive (CHC). The results were based on data from 573,680 women between ages 10 to 55. All of the participants were classified as “new users” of CHCs. Dr. Stephen Sidney, who is the lead author of the study and director of Research Clinics at the Kaiser Permanente Northern California Division of Research, said that although the overall risk of such events remains relatively small, “the growing number of studies showing an increased risk of venous thromboembolic events with drospirenone suggests that drospirenone-containing combined hormonal contraceptives should be used cautiously for women seeking hormonal contraception.”


Dropsirenone is a synthetic version of progestin, a naturally occurring female hormone. Drospirenone is an ingredient in newer combined hormonal contraceptives, including Yaz, Yasmin, Beyaz and Safyral. In April, the FDA updated the safety information on these birth control pills, warning that women who take these medications may be three times as likely to develop a blood clot.